• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      Podcast

      July: Episode 1     Watch time: 15 min

      Clinical trial spotlight – risankizumab and secukinumab head-to-head in plaque psoriasis

      The first episode focuses on the primary publication of IMMerge, a Phase 3, multicentre, randomised, open-label, efficacy assessor-blinded, 52-week study designed to evaluate the safety and efficacy of risankizumab compared with secukinumab in adult patients with moderate to severe plaque psoriasis.2

      Podcast Series Host

      Dr Laura Savage

      University of Leeds and Leeds

      Teaching Hospitals NHS Trust

      Podcast Guest Speakers

      Dr Amy Foulkes

      The University of Manchester

      Prof Brian Kirby

      St Vincent’s University Hospital,

      Dublin, Ireland

       

      Podcasts:

      JULY: Episode 1

      Clinical trial spotlight - risankizumab and secukinumab head-to-head in plaque psoriasis

      AUGUST: Episode 2

      Psoriasis in the time of COVID-19: an era of virtual clinics?             

      SEPTEMBER: Episode 3

      Psoriasis in practice: BAD guideline updates                               

      OCTOBER: Episode 4

      BAD 2020: virtual congress highlights

      NOVEMBER: Episode 5

      Are all IL-23s the same?                    

      DECEMBER: Episode 6

      EADV 2020: congress highlights       

      References

      1. SKYRIZI (risankizumab) Summary of Product Characteristics.
      2. Warren RB, et al. Br J Dermatol Published: Jun 28, 2020. doi: 10.1111/bjd.19341.

      UK-RISN-210512 Date of Preparation: November 2021